It may assist in identifying a sub-group of CLL patients who display abnormal C5 pattern and impaired activity, and are likely to be less responsive to immunotherapy treatment due to compromised CP activity and CDC. The gene discussed is CP; the disease is B-cell chronic lymphocytic leukemia.